"innovative capability" is a correct and usable phrase in written English.
It refers to a person or organization's ability to come up with new and creative ideas or solutions. Example: The company's success can be attributed to its strong innovative capability, which allows them to continuously introduce groundbreaking products to the market.
The results indicate that the dynamics of national systems of innovation is driven by the coevolution of three innovative capability variables (innovative input, scientific output and technological output), on the one hand, and three absorptive capacity factors (infrastructures, international trade and human capital), on the other.
We find that the strength of cooperative ties across a range of productive activities within the value chain are important facilitators for SME innovative capability; this is true for both product and process innovation.
This paper investigates the idea that the dynamics of national innovation systems is driven by the coevolution of two main dimensions: innovative capability and absorptive capacity.
The analytical results demonstrate that aligning intangible assets positively influence innovation process, and the organization capital mediates the relationship between intangible assets and innovative capability in the biopharmaceutical industry.
Reduced flexibility, a loss of innovative capability, and higher overhead may accompany efforts to cut costs.
In addition, Arthur Martin in France and Zoppas in Norway had strong local brand positions but limited innovative capability.
There are important similarities in national approaches to: enhancing innovative capabilities, breaking down innovation barriers, financing innovative activities often through innovative business models, collaborating with international firms, profiting from intellectual property, and to facing global competition.
With a continuous emphasis on drug innovation and global demand for innovative capabilities, Chinese CROs are prepared to take up increasingly important role as nexus of both external and internal pharmaceutical R&D efforts, and play a critical role in the pharmaceutical industry in China.
This research makes several contributions to improve the modelling of an open innovation strategy that can enhance the innovative capabilities of manufacturing enterprises based on the existing research.
Reversely, the strategic suppliers contribute greatly to technological innovation by relying on the comprehensive innovative capabilities from their R&D, production and quality assurance departments.
The argumentation is that the networks of experts, businesses, policymakers, and social organizations can generate institutional arrangements that enable innovations even in regions with low innovative capabilities [16 18].
